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Initially described as Th2 promoter cytokine, more recently, IL-33 has been recognized as
an alarmin, mainly in epithelial and endothelial cells. While localized in the nucleus acting as
a gene regulator, it can be also released after injury, stress or inflammatory cell death. As
proinflammatory signal, IL-33 binds to the surface receptor ST2, which enhances mast
cell, Th2, regulatory T cell, and innate lymphoid cell type 2 functions. Besides these Th2
roles, free IL-33 can activate CD8+ T cells during ongoing Th1 immune responses to
potentiate its cytotoxic function. Celiac Disease (CD) is a chronic inflammatory disorder
characterized by a predominant Th1 response leading to multiple pathways of mucosal
damage in the proximal small intestine. By immunofluorescence and western blot analysis
of duodenal tissues, we found an increased expression of IL-33 in duodenal mucosa of
active CD (ACD) patients. Particularly, locally digested IL-33 releases active 18/21kDa
fragments which can contribute to expand the proinflammatory signal. Endothelial
(CD31+) and mesenchymal, myofibroblast and pericyte cells from microvascular
structures in villi and crypts, showed IL-33 nuclear location; while B cells (CD20+)
showed a strong cytoplasmic staining. Both ST2 forms, ST2L and sST2, were also
upregulated in duodenal mucosa of CD patients. This was accompanied by increased
number of CD8+ST2+ T cells and the expression of T-bet in some ST2+ intraepithelial
lymphocytes and lamina propria cells. IL-33 and sST2 mRNA levels correlated with IRF1,
an IFN induced factor relevant in responses to viral infections and interferon mediated
proinflammatory responses highly represented in duodenal tissues in ACD. These findings
highlight the potential contribution of IL-33 and its fragments to exacerbate the
proinflammatory circuit and potentiate the cytotoxic activity of CD8+ T cells in
CD pathology.
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Interleukin-33 (IL-33) is a 30 kDa protein belonging to the IL-1
family, that is mainly expressed in the nucleus of fibroblasts,
subepithelial myofibroblasts (SEMFs), keratinocytes, adipocytes,
endothelial and epithelial cells from different tissues (1). Inside
the nucleus, IL-33 works as a nuclear factor influencing the
expression of several proinflammatory genes, such as IL8 and IL6
(2). Interestingly, like other IL-1 family members such as IL-1a,
IL-33 acts as an alarmin, being released from cells during a
programmed cell death like necroptosis and pyroptosis,
stimulating different immune responses (2). In contrast, when
cells die by apoptosis, IL-33 is cleaved by active caspase 3 or 7,
producing a non-bioactive form.
Remarkably, enzymes secreted by neutrophils or mast cells
like cathepsin G, neutrophil elastase, tryptase or chymase may
cleave free IL-33 producing diverse mature fragments of 18 to 21
kDa, having stronger bioactivities than the full-length form
(3, 4).
Soluble IL-33 was initially linked to a strong capacity to
stimulate Type 2 immune responses, through its actions on
Th2, Mast cells and ILC2 cell (5–7). However, increasing
evidence demonstrated that IL-33 is also able to promote
Type-1 immune responses (8), CD8+ T cytotoxic cells (9) and
invariant NKT cells activation (10), as well as, support regulatory
T (Treg) cell responses (11).
The cellular IL-33 receptor complex “IL-33R” is made up of 2
transmembrane proteins known as ST2L which, together with
the accessory protein IL-33Rb, binds to IL-33 mediating
intracellular signaling through the cytosolic adaptor MyD88,
which in turn activates the MAPK and other kinase cascades,
such as NF-kB, JNK, p38, and PI3K (12). ST2L is predominantly
expressed by Th2 lymphocytes, ILC2, Tregs, CD8+ T
lymphocytes, some active Th1 lymphocytes, monocytes, mast
cells, NKT and NK cells, macrophages, eosinophils and
mesenchymal cells (5, 13, 14). IL-33 also has a soluble binding
protein, named sST2, which is a spliced variant of the IL1RL1
gene lacking the transmembrane and intracellular domain of the
ST2L. When sST2 binds to extracellular IL-33, it avoids the
cellular signaling through the ST2L, therefore sST2 acts as a
decoy receptor regulating this axis (2).
IL-33 can be an important factor on gut homoeostasis
promoting a regulatory environment through its direct action
on Treg and ILC2 populations (15). Macrophages, ILC2 and
Treg cells can participate in the healing process dampening an
excessive local inflammatory response (16, 17). Moreover, IL-33
is involved in protection of gut epithelial barrier by regulation of
IgA production and secretion of RegIIIg (18, 19). Furthermore,
IL-33 allows differentiation of myofibroblast, which makes it an
important factor in wound healing, and fibrosis processes (20,
21). In the last years, IL-33 has become a novel focus of attention
in inflammatory disorders, such as inflammatory bowel disease
(22), infectious disease (23), and autoimmunity (24).
Since effects of IL-33 vary, being pro-tolerogenic or
proinflammatory depending on the context of the immune
response (13), to understand its role it is necessary to consider
which cells are involved as well as, the microenvironment whereFrontiers in Immunology | www.frontiersin.org 2IL-33 was released. Though the role of IL-33 has been evaluated
in gut inflammation (inflammatory bowel disease) (22), its
function has not been fully described in human small intestine.
Particularly, its capacity to act as an alarmin or cytokine, led us to
explore its role in the celiac disease (CD).
CD is a chronic gastrointestinal disorder developed in
genetically predisposed individuals after gluten intake. Typical
changes in proximal small intestine include villus atrophy, crypt
hyperplasia and lymphocytic infiltration in both epithelium and
lamina propria. The mucosal damage is driven by gluten-specific
CD4+ Th1 lymphocytes, that recognize gluten-derived peptides
presented in HLA-DQ2 or DQ8 molecules. However, innate
mechanisms must also be involved (25). IL-33 and sST2 levels
are increased in sera, as well their expression in duodenum of
pediatric CD patients, unveiling a link between IL-33/ST2 axis
and CD pathogenesis (26). In this work, we aimed to identify the
cells expressing molecules associated to IL-33/ST2 axis, to assess
the participation of IL-33 alarmin in potentiating local
inflammation and evaluate the connection with inflammatory
pathways in untreated celiac disease conditions.MATERIALS AND METHODS
Patients
Duodenal biopsies and blood samples were collected from active
celiac disease patients (ACD) and non-celiac (NC) individuals
during the routine protocol for CD diagnosis in the
Gastroenterology Units of Hospital Sor Marı ́a Ludovica
(pediatric patients) and Hospital San Martin (adult patients).
ACD was diagnosed by histological examination of duodenal
biopsies, serology (anti-transglutaminase 2, anti-deamidated
gliadin peptides and anti-endomysium antibodies), and the
evaluation of clinical presentation. The relevant clinical data of
each patient is presented in Supplementary Table 1.
Ethics Statement
All participants provided informed consent. The study was
approved by the Ethical Committees of both Public Health
Institutions and performed according to human experimental
guidelines. Clinical investigation was conducted according to
Declaration of Helsinki principles with participants identified
only by number.
Levels of ST2 and IL-33 in Serum
The concentration of IL-33 and sST2 in serum samples (100 ml)
was determined by commercial ELISA kits according to the
manufacturer ’s instructions (DuoSet, R&D Systems,
Minneapolis, MN, USA). Each sample was measured in
duplicated and average results were expressed as pg/mL.
Immunofluorescent Microscopy
Immunofluorescent assays for IL-33 were performed using
paraffine embedded samples. Duodenal samples were fixed
with 4% w/v formalin for 24 h at room temperature. Samples
were dehydrated and included in paraffin for further sectioning.October 2020 | Volume 11 | Article 581445
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deparaffinized and rehydrated in distilled water. Antigen
retrieval was performed by heat treatment in a Commercial
buffer CITRA PLUS Solution (Cat. HK080-9K, Biogenex). The
immunofluorescence analysis for ST2 was performed using
formalin fixed frozen samples. The tissues were fixed with 4%
w/v formalin, 30% w/v sucrose in phosphate buffer for about 24 h
at 4°C. After that, we included the tissues in a polyvinyl matrix
on a liquid nitrogen bath. Sections of 10 mm of samples where
used for immunofluorescence analysis. The tissues samples were
blocked using horse serum or fetal bovine serum at 5% in PBS,
and then incubated with primary antibodies for: CD90 (Abcam,
Cat# ab133350, RRID: AB_11155503, USA), CD31 (Abcam, Cat#
ab187377, RRID: AB_2756834, USA), CD11c (Abcam,
Cat# ab52632, RRID: AB_2129793, USA), CD45 (Abcam, Cat#
ab30470, RRID: AB_726544, USA); CD138 (DAKO, Cat#
M7228, RRID: AB_2254116, USA), CD3 (DAKO, Cat# M7254,
RRID: AB_2631163, USA); CD64 (Biolegend, Cat# 305012, RRID:
AB_528867, USA), CD20 (Affimetrix, Cat# 17-0209-71,
RRID: AB_469361, USA); T-Bet (Affimetrix, Cat# 45-5825-80,
RRID: AB_953658, USA); for human IL-33 (R&D Systems, Cat#
AF3625, RRID: AB_1151900, USA) and ST2 (R&D Systems, Cat#
AF523, RRID: AB_2125427, USA); mouse IL-33 (R&D Systems,
Cat# AF3626, RRID: AB_884269, USA) and suitable isotypes
controls from the same brands. After an overnight incubation,
the samples were washed with PBS buffer and then incubated with
secondary antibodies: anti-IgG(Mouse)-Alexa647 (Abcam, Cat#
ab150107, USA), anti-IgG(Rabbit)-Alexa647 (Abcam, Cat#
ab150075, RRID: AB_2752244, USA), anti-IgG(Goat)-Alexa488
(ThermoFisher, Cat# A32814, RRID: AB_2762838, USA). For
nuclear staining we used DAPI (ThermoFisher, Cat# D3571,
RRID: AB_2307445, USA) at 1 mg/ml.Images Analysis
Images were obtained using a SP5 Leica confocal microscope or
Apotome Zeiss microscope. The Fluorescence staining intensity
was obtained under the same acquisition parameters (light
intensity, sensor gain, and exposure time). The images were
analyzed by the FIJI software. Importantly, we performed a
manual segmentation of lamina propria sections as well as
epithelium compartment to quantify Total Fluorescent
Intensity per tissue area. We also determined a threshold
value of the fluorescent signals to be able to quantify it on
segmented areas. The threshold levels for quantification were
defined as grater as mean of isotype control plus 2 standards
deviations. Total Fluorescence per area was defined as relative
units of Fluorescence Intensity/Area (mm2), named here as
“Relative Fluorescence Density” or RFD. The total area inside
of the segmented compartments was calculated with a
threshold method known as “Huang” (27). This strategy
allows the use of the unspecific staining of cells as an
indicative of the total area, avoiding counting area of empty
space of the tissue or unprecise manual segmentation. On the
other hand, cell proportion was manually calculated counting
positive cells inside a manually predefined area on each
histological compartment.Frontiers in Immunology | www.frontiersin.org 3We performed an increment of contrast and brightness in all
the pixels for the images presented in this study in order to make
the staining clearer and more distinguishable for the readers.
However, these modifications were not performed during the
image’s analysis by the RDF or manual cell counting.
Cell Culture
HT-29 cells were cultured in Dulbecco’s Modified Eagle Medium
(DMEM) (Gibco, Invitrogen, USA) supplemented with 10% v/v
inactivated fetal calf serum (Gibco, Invitrogen, USA) with
streptomycin at 100 mg/ml and penicillin G at 100 U/ml. Cells
were cultured in 24 wells plate for 6, 24 or 48 h after incubation
with 100 mg/mL p31-43 (Genecust, Luxenburgh), 24 h with 50
ng/mL IFNg (R&D systems, Cat #285-IF-100, USA) and 6 h with
10 mg/mL Poly I:C (Sigma Aldrich, Cat # P1530-100MG, USA).
Western Blot Analysis
Duodenal biopsies were frozen on dry ice immediately after
obtention. Total protein was determined by standard procedures.
Briefly, tissue samples were incubated with protease inhibitor O
complete (Roche, USA), NP-40 (1% v/v) in a Tris buffer (pH:8.4).
The samples were minced using mechanical disruption. Total
protein concentration was determined following the instructions
of producer (Pierce™ BCA Protein Assay Kit, Thermofisher,
USA). Thirty micrograms of whole protein fraction were added
per well on a 10% or 14% acrylamide/bisacrylamide gel for ST2
or IL-33, respectively. The separation was performed with a
mini-Protean II Hercules (Bio-Rad, USA). Then, protein bands
were transferred to a nitrocellulose blotting membrane
(Amersham™ Protran® Western blotting membranes, USA).
After the corresponding blocking step, primary antibodies were
incubated on blocking buffer for 16 h at 4°C (5% w/v skimmed
milk on 0.1% Tween20-Tris Buffer). Primary antibodies used:
anti-mouse IL-33 (R&D Systems, Cat# AF3626, RRID:
AB_884269, USA) at 5 mg/ml, anti-human IL-33 (R&D
Systems, Cat# AF3625, RRID: AB_1151900, USA) at 5 mg/ml,
anti-human ST2 (R&D Systems, Cat# AF523, RRID:
AB_2125427, USA) at 1 mg/ml, the loading control was beta-
Actin (Abcam, Cat# ab8227, RRID: AB_2305186, USA) used at
0.2 mg/ml. Secondary antibodies were added for 1 h at 37°C.
Secondary antibodies: anti-IgG(Goat)-HRP (Abcam, Cat#
ab6885, RRID: AB_955423, USA) used at 1 mg/ml and anti-
IgG(Rabbit)-HRP (BioRad, Cat# 1706515, RRID: AB_11125142,
USA) used at 1 mg/ml. Chemiluminescent substrate
Amersham™ ECL™ Prime and images were obtained through
LI-COR® Scanner. Image analysis was performed with FIJI (FIJI
is just Image-J) software.
Mouse Model
C57BL/6 male mice (7–8 weeks old) were bred in the Animal
Care facility of the Facultad de Ciencias Veterinarias,
Universidad Nacional de La Plata. Mice were housed under
specific pathogen free conditions and allowed access to
autoclaved food and water ad libitum. We used different types
of stimuli: synthetic peptide p31-43, (LGQQQPFPPQQPY),
sequence derived from a-gliadin protein from wheat (Genecust,
Luxenburgh) and Poly I:C (Sigma Aldrich, Cat # P1530-100MG,October 2020 | Volume 11 | Article 581445
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in phosphate saline buffer (PBS), the peptide p31-43 was used at
20 mg/mice, Poly I:C was used at 30 mg/g of mice, both stimulus
together and PBS as control, were given in 200 ml using a curved
oral gavage needle (22G, 3.8 cm). Four or 16 h post-inoculation
mice were euthanized, and intestinal samples were collected for
western blot and histological analysis. All experimental
procedures were performed under appropriate local ethical
guidelines approved by the Institutional Animal Care and Use
Committee of the Facultad de Ciencias Exactas, Universidad
Nacional de La Plata (Protocol 009-27-17).
Histological Analysis
Sections of proximal small intestine of mice were fixed in 4% w/v
formalin, embedded in paraffin, and stained with H&E for
histological evaluation using a Nikon Eclipse Ti fluorescence
microscope with X-Cites Series 120 Q light source. Images were
taken with a Nikon Digital Sight DS Ri1 camera using Nis-
Elements software and measurements were performed using FIJI
software. Sections were scored in a blinded fashion, with at least 30
V/C (villus height/crypt depth) ratios assessed in eachmouse, while
intraepithelial lymphocytes (IELs) were counted in 10 randomly
well orientated villus tips and expressed as IELs/100 enterocytes.
Gene Expression Analysis
Duodenal samples from human patients were obtained in RNA
Later Solution (Biogenex) and stored until extraction at −80°C.
Total RNA was isolated with RNA Spin Mini kit (GE
Healthcare). Reverse transcription was performed using 1mg of
the total RNA using MML-V polymerase and random primers
from Molecular Probes Inc., (Invitrogen, Carlsbad, CA, USA)
were used. The Real-time PCR (qPCR) was performed using an
IQ-Cycler (Bio-Rad) with the SYBR Green Supermix
(Invitrogen, cat 11761-100, USA). EEF1A1 transcript was used
as housekeeping gene. The threshold cycle was used as indicative
of relative expression level, as described by Ginzinger (28).
Primer sequences used are listed in Table 1. The primers were
purchased from a local supplier (Genbiotech, Buenos Aires,
Argentina). The running protocol was the same for all
the transcripts: 95°C for 10 min and 50 cycles of 60°C for 15 s,
72°C for 45 s, and 95°C for 15 s.
Statistical Analysis
All the comparison between control subjects and active CD
patients, was performed using unpaired T-tests forFrontiers in Immunology | www.frontiersin.org 4parametrical data or Mann-Whitney for non-parametrical data,
while one-way ANOVA and Dunnett’s or Tuckey’s post-hoc test
was used when more than two groups were compared. The p-
value<0.05 was considered statistically significant. Statistical
analysis was performed with Prism 8 software (Graph Pad, San
Diego, USA).RESULTS
Active CD Patients Present Higher Levels
of Circulating IL-33 and sST2
Since one of the most important events in IL-33 signaling is its
release into the extracellular medium, we analyzed IL-33 and its
decoy receptor sST2 in serum samples of a local pediatric and
adult populations of active CD patients (ACD) and non-CD
(NC) controls. Both IL-33 and sST2 levels were found higher in
ACD patients compared with NC individuals (Figure 1).
Pediatric and adult samples showed similar distribution and
there was no difference when both populations were analyzed
separately (Supplementary Figure S1). Moreover, there were no
differences in sST2 and IL-33 serum levels when gender and
enteropathy score were considered (Supplementary Figure S1).TABLE 1 | Primers Used for RT-qPCR Analysis.
Gene Forward primer (5´->3´) Reverse primer (5´->3´)
IL33 AATCAGGTGACGGTGTTG ACACTCCAGGATCAGTCTTG
ST2L (IL1RL1) ATGTTCTGGATTGAGGCCAC GACTACATCTTCTCCAGGTAGCAT





EEF1A1 TCGGGCAAGTCCACCACTAC CCAAGACCCAGGCATACTTGAOctobeFIGURE 1 | Circulating levels of IL-33 and sST2 are higher in serum of active
celiac disease patients. Quantitative determination of IL-33 and sST2 was
performed in serum samples of active CD (ACD) patients and non-celiac (NC)
individuals using a commercial ELISA test. For IL-33, (ACD = 31, NC = 22)
and for sST2, (ACD = 32, NC = 23) serum samples were analyzed. Unpaired
t-test (**p < 0.01).r 2020 | Volume 11 | Article 581445
Perez et al. IL-33 Proinflammatory Fragments in GutThese findings demonstrate that a cellular source of IL-33 and
sST2 is actively releasing these molecules in ACD patients.
Duodenal Epithelium and Lamina Propria
of Active CD Patients Show Increased
Expression of IL-33 and ST2
To explore whether higher levels of IL-33 and sST2 found in the
serum of ACD patients are linked to changes in the duodenal
mucosa as a consequence of the enteropathy, indirect
immunofluorescence was used to evaluate the pattern of
expression of ST2 and IL-33 in duodenal mucosae sections of
ACD and NC individuals. The images obtained in duodenal
sections revealed that ACD patients present an increased IL-33
expression in the epithelium and crypts (Figure 2A). In a few
cases, a similar pattern was observed in control samples but with
lower fluorescence intensity (Figure 2A). In duodenal samples of
ACD patients, areas with cell infiltration and overexpression of
IL-33, close to the IL-33+ epithelial cells, were frequently
observed (arrows in Figure 2A). IL-33+ cells scattered in the
lamina propria, were also observed. Furthermore, both ACD
patients and controls showed a strong nuclear localization of IL-
33 in epithelial and lamina propria cells.
In order to assess the level of IL-33 expression in a
semiquantitative manner, the Relative Fluorescence Density
(RFD) was determined. Epithelium and lamina propria of ACD
patients presented an increased RFD values for IL-33 labelling
which were statistically higher than in control tissues (Figure 2B).
Noteworthy, cells containing IL-33 in the nuclei were not simplyFrontiers in Immunology | www.frontiersin.org 5scattered in the tissue, but they were distributed in a pattern
resembling structures associated with microvasculature (dashed
arrows, Figure 2A).
To understand the role of IL-33 locally, the expression of its
receptor was evaluated by immunofluorescence on duodenal
sections. ST2 showed a high expression in mononuclear cells of
lamina propria and weak staining in the epithelium (Figure 2C).
Moreover, the epithelium and lamina propria of ACD patients
showed a statistically higher expression of ST2 compared with NC
controls by semiquantitative RFD evaluation (Figure 2D).
Cleaved IL-33 and sST2 Are Increased in
Duodenal Tissue of Active CD Patients
Next, western blot analysis was performed to further evaluate the
level of ST2 and IL-33 on whole duodenal biopsies of ACD
patients and NC population. Western blot analysis showed
different fragments of IL-33: a full-length band (~34 kDa), and
other three protein bands with smaller molecular sizes (18, 21
and 25 kDa). The ~25 kDa band corresponds to cleaved IL-33,
probably by the action of apoptotic Caspase 7 or Caspase 3 into
its inactive form as described by Lüthi (29) (Figure 3A). The
bands with a molecular mass in the range of 18-21kDa,
correspond to potentially active IL-33 (3, 4). Interestingly, 18
and 21 kDa IL-33 fragments were increased in samples from
ACD patients (Figure 3B) and this was also observed when the
ratio of 18 and 21 kDa fragments were referred to total IL-33
(Figure 3C). These results highlight an increased bioactive
cleaved IL-33 forms in duodenal tissue of ACD patients.A
B
DC
FIGURE 2 | Higher expression of IL-33 and ST2 in duodenal epithelium and lamina propria region of active CD patients. (A) Representative images of IL-33
immunofluorescent staining in duodenal mucosae of NC and ACD patients. IL-33 (green), Nuclei (blue). The white arrows show some of the regions with expression
of IL-33 associated to cell infiltration. Dashed arrows show cells with IL-33 nuclear localization with a morphology compatible with vascular cells. (B) Relative
Fluorescent Density (RFD) of IL-33 in the epithelial compartment and lamina propria. NC (n = 7), ACD patients (n = 10). (C) Representative images of ST2
immunofluorescent staining in duodenal mucosae of NC and ACD patients. ST2 (green), nuclei (blue). (D) RFD of ST2 in the epithelial compartment and lamina
propria. NC (n = 4) and ACD patients (n = 6). Unpaired t-test (*p < 0.05; **p < 0.01). The images in A were taken with Leica SP5 microscope with 20X objective and
the images in C were taken with Zeiss Apotome with 20X objective.October 2020 | Volume 11 | Article 581445
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forms were increased in duodenal tissues of ACD patients
(Figures 3D, E). Several bands were found for ST2L that may
be produced by heterogeneous glycosylation of this receptor as
described by Tago (30) and Yoshida (31) while for sST2 only a
band of about 57 kDa was found. Together, these results showed
an increase in the total expression of ST2 on duodenal mucosae
of ACD patients. Both ST2 forms were higher in ACD samples
but relative levels of ST2L/sST2 were similar when ACD and NC
populations were compared (Figure 3F), indicating a similar
upregulation of both proteins in ACD patients.
Characterization of IL-33+ Cell Populations
in the Small Intestinal Mucosa
Since IL-33+ cells were found abundantly distributed in the nuclei of
lamina propria cells with a distribution and arrangement resembling
myofibroblast or endothelial cells from microvasculature-like
structures (Figure 2A), we performed a series of double indirect
immunofluorescence assays to co-stain IL-33 and characteristic
markers of mesenchymal cells (SMA, CD90), dendritic cells
(CD11c), macrophages/neutrophils (CD64), B cells (CD20) and
the pan-leukocyte marker (CD45) (Figure 4).
Cells associated with structures resembling microvasculature
and containing IL-33 in the nuclei were identified as endothelial
CD31+ cells (Figure 4A). Other IL-33 nuclear positive cellsFrontiers in Immunology | www.frontiersin.org 6expressed SMA and CD90 (Figures 4B, C) identifying them as
mesenchymal cells, mainly myofibroblast and pericytes around
vascular and crypt structures immersed in the lamina propria.
Interestingly, a vast majority of IL-33+ cells in ACD patients were
close to the villi’s epithelium (white arrows in Figure 2A), some
of these cells presented a cytoplasmatic expression
(Supplementary Figure S2). Moreover, using a panel of
antibodies, some of these IL-33+ cells were characterized as
CD45+ (Figures 4D, E) CD11c+ (Figure 4F), CD20+ (Figure
4G) or CD64+ cells (Figure 4H) and some were weakly CD31
positive (Supplementary Figure S2C). IL-33+ cells in the
epithelial compartment where EPCAM+ CD45- cells which
identifies them as epithelial cells (Figures 4D, I). These
findings suggest that IL-33 can be released by different types of
cells from the duodenal mucosa, particularly by infiltrating
mononuclear cells, like B cells, macrophages and dendritic
cells. Endothelial and epithelial cells can also act as a source of
IL-33 in the extracellular space upon activation.
Analysis of In Vitro and In Vivo Expression
of IL-33 Upon Proinflammatory Stimulation
Since expression of IL-33 was up-regulated in duodenal mucosa
of ACD patients, a tissue suffering from a chronic inflammatory
condition, we aimed to assess whether proinflammatory stimuli
can modulate IL-33 expression in this condition. Based on theirA B
D E F
C
FIGURE 3 | Increased levels of cleaved IL-33 fragments, ST2L and sST2 in duodenal samples of active CD patients and controls. (A, D) Representative images of
Western blot analysis for ST2L and sST2 or the different cleaved IL-33 (25kDa, 21/20kKDa or 18kDa) or full protein (34kDa) fragments. Beta actin was used as the
loading control protein in all cases. (B) Ratio of signal density of each of the IL-33 forms and beta-actin (NC = 7 and ACD = 9). (C) Relative proportion of each of IL-
33 fragments for ACD and NC populations (NC = 7 and ACD = 9). (E) Ratio between signal density of bands corresponding to ST2s (NC = 10 and ACD = 13) or
ST2L (NC = 10 and ACD = 12) and beta-actin signal. (F) Ratio between signal density of ST2L and ST2s for ACD and controls (NC = 10 and ACD = 12). In B, the
median value is represented with a horizontal line for each population. for ACD and controls. The C, E, F plots are shown with average bars plus SEM bars. t-test
with Welch was performed. Mann Whitney Test was performed for IL-33 relative to beta actin analysis (*p < 0.05; **p < 0.01; ***p < 0.001). Beta-Actin was used as
loading control. R.U., Relative units.October 2020 | Volume 11 | Article 581445
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peptide p31-43 (34, 35), as well as a synthetic TLR3 ligand, poly
I:C, which is known to induce IL-33 expression in different cell
lines and murine models (36–38) were evaluated in an in vitro
assay using the human intestinal epithelial cell line, HT29. Poly
I:C strongly induced IL-33 transcript in HT-29 cells, with no
differences for the other inflammatory treatments (Supplementary
Figure S3). According to these findings and considering previous
works on an experimental model of enteropathy developed in wild
type mice (34, 35), we aimed to study whether an acute
inflammatory stimulus, intragastric p31-43 and poly I:C
treatments, was able to upregulate IL-33 expression in vivo. We
showed previously that intragastric treatment with p31-43, causes
inflammasome activation and IL-1b production, increased number
of IELs and reduction of V/C ratio (34), while poly I:C, induces an
inflammatory reaction including increased number of IELs,Frontiers in Immunology | www.frontiersin.org 7reduction of V/C ratio, and upregulation of IFNb and IFNg
expression (35). All stimuli tested were able to induce an increase
of the IELs numbers and reduction of V/C ratio, confirming the
inflammatory response produced upon these treatments
(Supplementary Figure S4). IL-33 production was induced in
total mucosae and particularly in epithelial cells of mice treated
with poly I:C or poly I:C+p31-43, being the higher fluorescence
signal found in epithelial and lamina propria cells from poly I:C
+p31-43 treated mice (Figures 5A–C). Concordantly, western blot
analysis showed that total IL-33 was induced predominantly in poly
I:C+ p31-43 treatment (Figures 5D, E). This difference may be
explained by a possible synergic action, since poly I:C and p31-43
may drive different signaling pathways exacerbating the
inflammatory reaction on mucosal intestinal cells, mainly on
epithelial cells (Figure 5B). This hypothesis may explain why




FIGURE 4 | IL-33+ cells in Duodenal Mucosae of active celiac patients. Representative images of immunofluorescence analysis of duodenal sections of active
CD patients. IL-33 (green), nuclei (blue). Other markers in red. In some images the epithelial compartment was delimited with white dashed lines. (A). CD31+
endothelial cells expressing IL-33 (white arrows). (B) Smooth muscle actin in red and white lines delineated intestinal crypts. The white arrows point to SMA+IL-
33+ cells which are located around vascular structures and crypts. (C) Some of the IL-33+ CD90+ cells are pointed by a white arrow. (D, E) CD45+IL-33+ cells
in lamina propria, but not in epithelial compartment. (F) A few IL-33+CD11c+ where close to the epithelium of ACD patients. (G) Some of the CD20+IL-33+ cells
are pointed with white arrows. (H) Some of the lamina propria double positive IL-33+ CD64+ are pointed with white arrows. (I) EPCAM+ IL-33+ cells are pointed
with white arrows. The images were taken with 20X and 63X objectives from the SP5 Leica Microscope and objectives 20X, 40X and 60X from the Apotome
Zeiss microscope.October 2020 | Volume 11 | Article 581445
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compared, although the rate of production of IL-33 was increased.
These findings suggest that IL-33 expression can be induced by
signals derived upon triggering TLR3/RIGI and enhanced by
proinflammatory effects of p31-43.
ST2+ CD8+ T Lymphocytes Are Increased
in CD Samples
As total ST2 expression was increased on whole tissue on both
epithelial and lamina propria compartments of duodenum in
ACD patients, we aimed to identify the ST2+ cells populations.
Since many of the ST2+ cells were mononuclear cells infiltrating
the epithelium and lamina propria, most of themwere hematopoietic
derived CD45+ cells (Figure 6A), as we found an increase in RDF of
ST2 staining in CD45+ (Supplementary S5A), as well as, in theFrontiers in Immunology | www.frontiersin.org 8cellular proportion of ST2+ cells in the CD45+ population in ACD
patients (Figure 6B). We also found that many of the CD45+ cells
were T lymphocytes (CD3+ cells) (Figure 6A). Moreover, many of
the ST2+ cells were CD8+ cells scattered though the lamina propria
and in the epithelial compartment (Figure 6A).
Though percentage of CD3+ST2+ in ACD and controls were
similar, the amount of CD3+ST2+ cells in the epithelial compartment
was significantly increased in the ACD population (Figure 6C).
Remarkably, among T lymphocytes, we found a higher number of
CD8+ST2+ cells in the epithelial compartment and in the lamina
propria of ACD samples (Figure 6D). These results point out to a
selective increase in the number of ST2+CD8+ T lymphocytes in the
ACD population. The CD8+T cells also have an increase in RDF on
both lamina propria and epithelium compartments (Supplementary




FIGURE 5 | Induction of IL-33 in an acute inflammatory response in a mice model. (A) Representative images of immunofluorescence analysis of duodenal
sections of each of mice treated with: PBS, p31-43, PIC or PIC+p31-43. The IL-33 staining is shown in green and Cell Nuclei in blue. (B) Results of IL-33+ cell
density on total mucosae, epithelium or lamina propria for each of the conditions. (C) Results of IL-33+ RFD analysis on total mucosae, epithelium or lamina
propria for each of the conditions. (D) Representative western blot analysis of IL-33 analysis in whole mucosae of each of the conditions. (E) Results of the
analysis of IL-33 western blot for each of the conditions relative to beta actin signal and control stimuli (PBS). One-way ANOVA, post-test Tukey. (*0.01 < p <
0.05, **0.001 < p < 0.01, ***p < 0.001).October 2020 | Volume 11 | Article 581445
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were found spread through the lamina propria but also in the
epithelial compartment in ACD patients.
ST2+ cells in the epithelial compartment were identified as
CD45-ST2+ or CD3-ST2+ cells and were mostly present on the
luminal epithelium. Noteworthy, a high number of plasma
cells (CD138+) with a mild cytoplasmic expression of ST2 on
both ACD and controls was found. In addition, 40 to 50% of
the CD64+ cells were ST2+ cells, likely macrophages (Figures
6E, F); however, CD64+ neutrophils cannot be ruled out. On
the other hand, we found a few SMA+ cells, probably
myofibroblast close to the luminal epithelium, though due
to uneven SMA staining inside the cytoplasm, the counting
could not be performed.Frontiers in Immunology | www.frontiersin.org 9IL-33/ST2 Axis Components Correlates
Positively With IRF1 in Inflamed ACD and
Healthy Duodenal Mucosa Tissue
To explore the relationship between IL-33/ST2 axis with genes
related with inflammatory conditions we performed a correlation
analysis from ACD and healthy NC. We found that none of the
IL33/ST2 axis components were upregulated in ACD patients
(Figure 7A). Next, we assessed the potential connection of the
IL-33/ST2 axis with other celiac disease associated cytokines and
intracellular factors (Figure 7B), particularly, interferon gamma
IFNG (32, 33), Interferon beta IFNB1 (39, 40), IL10 (41) and the
IRF1 factor (42, 43). IFNG/IL10 and IFNB1/IL10 ratios were




FIGURE 6 | Characterization of ST2+ cells in duodenal mucosa. (A) Representative images of immunofluorescence analysis of duodenal sections of active CD
patients. ST2 (green), nuclei (blue). Other markers in red. Epithelial compartment was delimited with white dashed lines. White Arrows indicate some of the double
positive cells for ST2 and CD45, CD3, CD8, CD138, SMA and CD64. White dashed arrows indicate ST2 expression in epithelial cells. Counting of double positive
CD45+ST2+ (NC = 4, ACD = 6). (B) CD3+ST2+ (NC = 5, ACD = 5). (C) CD8+ST2+ (NC = 5, ACD = 6). (D) cells in the whole mucosae (Total), in the epithelium and in
the lamina propria compartment for active CD and control patients. Counting of double positive CD138+ST2+ (NC = 5, ACD = 6) (E) and CD64+ST2+ cells (NC = 3,
ACD = 6) (F) in the whole duodenal mucosa. T-test was used as Statistical analysis with Welch correction if needed. The p-value < 0.05 was considered statistically
significant (*p < 0.05). All the images were taken with Zeiss Apotome with objective 40X.October 2020 | Volume 11 | Article 581445
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have a mild positive correlation with each other (Figure 7C).
Particularly, IL33 showed a mild correlation with the IFNB1/
IL10 ratio (Figure 7D). Though none of the transcripts
correlated with IFNG or IFNB1, they were linked to IFN
induced transcriptional factor-1, IRF1 (Figure 7E). Altogether,
these findings suggest a regulation of IL33 and sST2 expression
by IFNs (Figure 7F).DISCUSSION
IL-33 is a potent alarmin that can be released from different cells
under stress conditions and necrotic death (44). Mouse models
(9, 11, 45, 46) and disease conditions where IL-33 is released,
have shown that biological consequences over the immuneFrontiers in Immunology | www.frontiersin.org 10response depend on the tissue environment (13, 22, 23, 47).
Different human disorders involve IL-33 as a potent trigger of
inflammatory processes, such as Rheumatoid Arthritis, Systemic
Sclerosis, Sjörgen Disease and Psoriasis (47–50). In addition, free
IL-33 may act as a potent inducer of regulatory T cell (Tregs)
responses (11). Alternatively, IL-33 is able to act on pro-
tolerogenic dendritic cells that potentiate Tregs polarization by
increasing IL-2 production. Also, IL-33 acts directly on Treg
ST2L+ cells inducing their proliferation.
Particularly, IL-33 plays a role in gut homeostasis by
regulating local microbiota through the induction of IgA (18)
and antimicrobial peptide production (19). IL-33 is involved in
gastrointestinal pathologies, such as ulcerative colitis, where IL-
33 is upregulated and believed to potentiate Th2 responses (21,
22, 51). This is also supported by the amelioration of ulcerative




FIGURE 7 | Correlation between the IL33/ST2 axis and inflammatory markers in duodenal mucosae. (A) Violin plots of qPCR results for IL33 gene (NC = 11, ACD =
15) and IL1RL1 splice variants corresponding to sST2 (NC = 10, ACD = 12) and ST2L (NC = 5, ACD = 7) proteins. (B) Correlation heatmap of Pearson r values
between different genes evaluated in ACD and NC individuals. (C) Correlation plot of sST2 mRNA with IL33 mRNA. (D) Correlation plot of ratio IFNB1/IL10 with IL33
mRNA. (E) Correlation plot of IRF1 mRNA with IL33 mRNA. (F) Correlation plot of IRF1 mRNA with sST2 mRNA. All ACD samples are shown as red dots and NC as
blue dots, p-value is shown for each correlation. Unpaired T-test was used as the statistical analysis in (A) and Pearson correlation analysis for multiple correlations
of different genes in (B–E). The p-value < 0.05 was considered statistically significant.October 2020 | Volume 11 | Article 581445
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IL-33 potentiating proinflammatory responses, but also promoting
Treg cells and amphiregulin release from ILC2 cells (15).
Nevertheless, it is known that certain proinflammatory
cytokines, such as IL-23p19 can deactivate this pro-tolerogenic
mechanism of IL-33 by targeting Treg directly (11). Moreover,
IFNg derived from viral or bacterial infections acts as an
inhibitor of IL-33 driven pro-Th2 responses, as inhibiting ILC2
responses to IL-33 (53).
The inflammatory response enables IL-33 to control cells
involved in Type 2 immune responses to strongly potentiate
cytotoxic activity. In a pro-Th1 environment, as reported in some
viral infections, cytotoxic CD8+ T cells and NK cells may produce
ST2L (9, 54–56) and IFNg to expand the Th1 response (57).
In damaged tissues, release of sST2, as decoy factor, limits the
effect of free IL-33 (22, 58–60) and increases IL-33 response
threshold in the microenvironment where both coexist (13, 61).
As mentioned above, necrotic or stress cells are believed to be a
source of free IL-33. Thus, in an inflammatory setting, the
relative abundance and localization of ST2+ cells, local sST2
release, and presence of cytokines, such as IFNg and IL-23, will
determine the biological effects of IL-33.
Celiac disease (CD), a chronic immunemediated pathology, is an
example of these two functional roles of IL-33, where an exacerbated
cytotoxic response against stressed cells is accompanied by an intense
but ineffective pro-regulatory response (62–67).
To investigate the link between IL-33 and CD, we assessed the
levels of IL-33 and ST2 in a local pediatric and adult population
of CD patients at diagnosis and non-celiac controls. We found
that concentration of IL-33 and sST2 in serum were higher in
ACD than in NC population. Levels of both proteins were higher
than those reported for a Spanish population by Lopez Casado
(26), probably due to difference in the commercial test used.
Immunofluorescence assays on sections of duodenal
biopsies showed that expression of IL-33 and ST2 is increased
in ACD patients. Quantitative analysis of intensity of fluorescence
(RFD) and western blot analysis showed that expression of IL-33
and its receptor were upregulated in duodenal mucosa in ACD
patients. In contrast, the mRNA levels of IL-33 and ST2L or sST2
did not show an upregulation in ACD samples, this is probably
due to a dilution effect when mRNA levels were determined in the
whole tissue or difference in post-transcriptional regulation
increasing IL-33 or ST2 protein expression (68–72). Overall,
these findings suggest that the main source of circulating IL-33
and sST2 in ACD patients is the small intestinal mucosa.
Moreover, immunofluorescence analysis confirmed that IL-33 is
produced by a great variety of cells. Particularly, IL-33 was found
in epithelial cells, endothelial cells and myofibroblasts. In fact, in
many of these cells, IL-33 was found having a nuclear and
cytoplasmic localization, suggesting its potential release from
these cells (51, 73, 74). Furthermore, IL-33+ cells were also
found in the inflammatory infiltrate, corresponding to CD11c+
dendritic cells, CD20+ B cells, and CD64+ cells, probably
monocytes/macrophages. Accordingly, upon stimulation with
gliadin peptides, PBMCs from ACD patients were able to
release IL-33 in the culture medium (26).Frontiers in Immunology | www.frontiersin.org 11The release of IL-33 may induce different immune responses
depending on the target cells present in the surrounding tissue. In
intestinal mucosa in CD enteropathy, NK, NKT and cytotoxic T
cells are potential targets for IL-33 (26). These cell populations,
increased in CD duodenum, are known to play an important role in
CD pathology (75, 76), and are also targeted by free IL-33 on viral
infections (46) and certain tumor environments (77). Significantly,
IL-33 can enhance cytotoxic responses and induce IFNg release by T
CD8+ cells, by potentiating the effects of IL-12 and enhancing T-bet
and BLIMP1 expression (9, 13, 54, 78). In this scenario, IL-33 could
enhance cytotoxic mechanisms and pro-Th1 immune response in
CD pathogenesis. The increased number of CD8+ST2+ cells on both
epithelial and lamina propria compartments pointed toward this
hypothesis. However, we cannot rule out the possibility of IL-33
acting on Treg, ILC2 or Macrophage/Dendritic cells to promote
different immune responses.
Levels of sST2 were higher in peripheral blood and duodenal
tissue of ACD patients, suggesting that it may act as a decoy
factor in intestinal tissue modulating the biological activity of IL-
33. However, upregulation of both splice variants of ST2: ST2L
and sST2 and sST2/ST2L ratio were similar in ACD and NC
populations, suggesting that target ST2+ cells may respond to free
IL-33 in ACD intestinal mucosa when its local concentration
exceeds the sST2 levels.
Since IL-33 may have different functions according with the
tissue environment (61), distinct scenarios can be proposed in small
intestine in ACD. Through Tregs and ILC2 cells, IL-33 would
participate as a pro-tolerogenic and wound healing cytokine, but
these effects can be inhibited by sST2. Accordingly, higher levels of
sST2, as a proinflammatory factor, were associated with tissue
damage and inhibition of the wound healing process induced by IL-
33 (22, 58, 79). Additionally, IFNg and IL-23, cytokines produced
upon gluten stimulation in ACD (33, 80), are strong inhibitors of
IL-33 induced effects on ILC2, Th2 and Treg cells (11, 53). Since we
found an increase in CD8+ST2+ cells in small intestine in ACD, a
disorder characterized by a Th1 response and cytotoxic activity
carried out by CD8+ T cells (67, 75, 81), the scenario where IL-33
potentiates cytotoxic functions is more likely to happen.
Posttranslational modifications of IL-33 are critical for its
interaction with ST2L. These modifications depend on the
activity of specific proteolytic enzymes, which may be induced
or activated under specific conditions (13). Particularly, proteases
as effector caspases in apoptosis and some proinflammatory
enzymes secreted by Neutrophils and Mast cells can substantially
modified IL-33 bioactivity. The cleavage of IL-33 by caspase-3 or 7
during apoptosis renders inactive IL-33 fragments of about 25 kDa
and 6.5 kDa (29). Our western blot setup cannot detect fragments
under 12 kDa threshold. Therefore we did detect the 25 kDa
fragment but the 6.5 KDa fragments could not be analyzed.
Interestingly, ACD patients present active apoptotic mechanisms
in different cells, but particularly in epithelial cells (82, 83). As a
consequence, IL-33+ cells such as epithelial or endothelial cells, may
undergo apoptosis in CD intestinal mucosae and produce inactive
25 kDa IL-33 fragments. Unlike apoptosis, other programmed cell
death mechanisms such as pyroptosis and necroptosis release
cellular components and alarmins as IL-33 with proinflammatoryOctober 2020 | Volume 11 | Article 581445
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cannot assumed that all the 25 kDa fragments are derived from
apoptotic cells, since Tryptase from Mast cells cleaves full IL-33
yielding fragments between the aminoacidic positions 72–270 and
79–270 which have a mass of about 25 kDa (4). Additionally, we
detected 18 and 20/21 kDa IL-33 fragments having stronger
bioactive effect than native full-length IL-33 (3, 4). These IL-33
fragments result from digestion by enzymes, such as cathepsin G,
neutrophil elastase, tryptase or chymase, derived from neutrophil
or mast cells. Lefracais et al, (3, 4) have reported that enzymes
secreted by Neutrophils (Cathepsin G and Neutrophil Elastase) or
Mast cells (Chymase, Tryptase) can produce fragments of about 18/
19 and 20/21 KD comprising aminoacidic positions: 95–270, 99–
270, 107–270, and 109–270 from full IL-33. Since our western blot
sensitivity did not allow us to differentiate variation of about 1 kDa
in the fragments mass, we considered these 18/21 kDa fragments as
mature forms of IL-33 reported in literature (3, 4). Interestingly,
both mast cells (87, 88) and neutrophils (89) are increased in
number and activity in duodenal mucosa in active CD, suggesting
both increased IL-33 release and its processing in the extracellular
space occurs simultaneously, resulting in inflammatory duodenal
mucosa environment in ACD patients. Moreover, based on their
proinflammatory activity, 20/21 kDa IL-33 fragments have also
been proposed as a potent vaccine adjuvant to enhance IFNg+
CD8+ T cell responses against certain viruses, such as HPV (90, 91).
As shown here, some of the CD8+ST2+ cells were found in the
intraepithelial compartment, where intraepithelial lymphocytes,
recognized as tissue-resident cytotoxic T lymphocytes playing a
critical role in CD pathogenesis (75, 92). Interestingly, the
transcription factor T-bet, master transcription factor for
differentiation of Th1 and cytotoxic T lymphocytes (93), was found
in a population of ST2+ cells spread through the lamina propria and
in the epithelial compartment in CD patients. Collectively, we suggest
that recently released IL-33 can be processed by enzymes from mast
cells or neutrophils, resulting in 18/21 kDa fragments with increased
affinity to ST2L and higher potency to activate cytotoxic ST2L+CD8+
T cells in duodenal mucosae of CD patients.
When IL33/ST2 axis transcript were evaluated, a mild
correlation was found. This is concordant with reports
showing that IL-33 controls the transcript levels of ST2L and
sST2 in a concentration dependent manner (94). Interestingly,
IL-33 and sST2 transcript correlated with IRF-1 mRNA levels,
which was found to be essential for IL-33 production under viral
infections in endothelial cells (95). Type I and II IFNs regulate
IRF-1 expression in different cells (43, 96, 97), suggesting a
possible indirect regulation of IL-33 expression by IFNs
highlighting the need to further investigate the link between
IL-33/ST2 axis and IFNs in the context of CD.CONCLUSIONS
The inflammatory network operating in small intestine mucosa is a
consequence of an immune response to wheat proteins in CD
patients. On a normal diet, local inflammation can be exacerbated
through IL-33 release by programmed cell death and further
production of 18/21 kDa IL-33 fragments, additionally potentiatingFrontiers in Immunology | www.frontiersin.org 12cytotoxic ST2L+ CD8+ T cells. Since these mechanisms can be
potentiated in tissues where IL-33 is secreted or released by means
of proinflammatory death mechanisms, different IL-33 target cell
populations may play a role in the pathogenesis of celiac disease.DATA AVAILABILITY STATEMENT
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